VALARTH See Cipla in the appOpen in app
CIPLA · NSE · Pharmaceuticals

Cipla Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Large Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
cheap low confidence No valuation within 120 days; P/E 31.2 vs peers 39.3 (6th of 21); P/B 2.9 vs peers 6.2 (4th of 22).
Cheap for a reason: A negative 5-year return.
Statements through FY2026Prices adjusted for 1 corporate actionNot yet reviewed by the adversarial model

What is Cipla's share price today?

Cipla last traded at ₹1,311.30 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.8% on the day, down 16.8% over a year. Its 52-week range is ₹1,166 to ₹1,673. The live price is in the app.

₹1,311.30 +0.8% today
−16.8% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Oct 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range29% of the way up
Low ₹1,166High ₹1,673

What is Cipla's market cap?

Cipla's market capitalisation is about ₹1.05 lakh crore: what it would cost to buy every share at today's price. That makes it the 92nd largest large cap company we cover.

₹1.1 L Cr Large Cap92nd largest large cap company
Large Cap means the 100 largest listed companies, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: CIPLA
ISIN
INE059A01026
Cap bucket
Large Cap, 92nd largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
1995
Futures and options
Traded

Is Cipla overvalued?

Cheap, with low confidence: no valuation within 120 days; P/E 31.2 vs peers 39.3 (6th of 21); P/B 2.9 vs peers 6.2 (4th of 22). Cheap for a reason: A negative 5-year return.

Valuation

Latest price and trailing 12 months
P/E 31.17
vs peers 39.3 · 6th of 21
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 2.89
vs peers 6.2 · 4th of 22
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹1.05 lakh Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield Not available
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) Not available
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth 2.73
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Cipla a quality business?

Quality score 48.8, 14th of 21 in its peer set; WATCH on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 48.8
vs peers 54.7 · 14th of 21
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level WATCH
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 10.6%
vs peers 15.9% · 19th of 22
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 13.9%
vs peers 18.8% · 16th of 22
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 11.6%
vs peers 14.3% · 15th of 21
Profit after everything, as a share of revenue. Learn more →
EPS ₹47.91
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Cipla made money for shareholders?

Mixed: −16.8% over one year and +6.5% a year over five years.

Shareholder returns

1-year return −16.8%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +6.5% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer Yes
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−2.6%
1M
−3.7%
3M
−8.8%
6M
+7.4%
1Y
−16.8%
3Y
+3.9%
5Y
+6.5%

Does Cipla pay a dividend?

Cipla last paid ₹13.00 a share, ex-dividend 5 Jun 2026; nothing in the past 12 months counts toward a yield.

Dividends

Per share, by ex-dividend date
5 Jun 2026 · Final₹13.00
27 Jun 2025 · Special₹3.00
27 Jun 2025 · Final₹13.00
2 Aug 2024 · Final₹13.00
21 Jul 2023 · Final₹8.50
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Cipla growing?

Revenue 3 years 8.3% a year; profit 3 years 11.4% a year; revenue 5 years -0.6% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 8.3% a year
vs peers 14.0% · 18th of 21
Compound annual growth of revenue over three years. Learn more →
Profit 3 years 11.4% a year
vs peers 20.2% · 16th of 20
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years -0.6% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 6.0% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years 11.4% a year
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 10.0% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history -9.0%
vs peers 15.7% · 6th of 18
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Cipla do last quarter?

Cipla reported revenue of ₹7,077 Cr, up 5.3% on a year earlier and a net profit of ₹787 Cr, down 26.9% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹7,077 Cr
+5.3% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹787 Cr
−26.9% on a year earlier
What was left for shareholders after every cost and tax.

How does Cipla compare with its peers?

Compared with 21 Pharmaceuticals; 6th of 21 on P/E; 14th of 21 on quality score.

Compared with 21 Pharmaceuticals

21 companies

Cipla against its peers

Largest 10 of 21 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Cipla Ltd₹1.1 L Cr31.22.910.6%13.9%−16.8%
Divis Laboratories Ltd₹2.5 L Cr84.89.416.5%21.4%+42.5%
Torrent Pharmaceuticals Ltd₹1.8 L Cr74.316.927.3%19.2%+32.4%
Zydus Lifesciences Ltd₹1.1 L Cr24.93.715.9%15.9%+12.3%
Laurus Labs Ltd₹1.1 L Cr100.510.215.1%14.9%+132.9%
Dr Reddys Laboratories Ltd₹99,911 Cr30.93.310.7%12.6%−5.2%
Mankind Pharma Ltd₹97,830 Cr47.95.013.3%13.1%−3.0%
Aurobindo Pharma Ltd₹97,411 Cr26.43.311.2%12.9%+48.9%
Lupin Ltd₹89,469 Cr15.83.523.4%27.5%−0.8%
Glenmark Pharmaceuticals Ltd₹64,714 Cr36.02.53.9%6.3%+20.1%
Alkem Laboratories Ltd₹63,118 Cr29.34.517.3%18.8%−3.9%
Peer median—39.36.215.9%18.8%+33.1%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Cipla?

Cipla is held by promoters 29.1%, foreign institutions 20.1%, domestic institutions 34.5%.

Shareholding pattern

Latest filing, percent of shares
Promoters29.1%
The founders and controlling group.
Foreign institutions20.1%
Overseas funds investing through the FPI route.
Domestic institutions34.5%
Indian insurers, banks, pension and mutual funds together.
Mutual funds20.5%
Indian mutual fund schemes; part of domestic institutions.
Retail and others6.8%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Cipla?

37 analysts cover Cipla, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

37 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Cipla do and what is it sensitive to?

Cipla Ltd is a pharmaceutical company that manufactures and sells branded prescription drugs, trade generics, consumer health products, and active pharmaceutical ingredients (APIs) across India, North America, Africa, and emerging markets. Sensitive to: foreign exchange rates.

Business-model card

FY2026 · 43 verified
4Revenue
5Channels
2Regulators
3Reg. dependencies
3Sensitivities
2Costs
3Geographies

Cipla Ltd is a pharmaceutical company that manufactures and sells branded prescription drugs, trade generics, consumer health products, and active pharmaceutical ingredients (APIs) across India, North America, Africa, and emerging markets. It earns revenue through sales of prescription medications, generic drugs, over-the-counter consumer wellness brands, and APIs to hospitals, pharmacies, distributors and consumers.

Revenue by segment

year ended March 31, 2025 (FY25), consolidated
India (Rx + Gx + CHL)38.8%
North America26.4%
One Africa12.8%
South Africa9.8%
Emerging Markets and Europe11.0%
Others1.1%

Revenue engine

4 verified
One India (Branded Prescription, Trade Generics, Consumer Health) (49.0%)
Cipla maintains #2 market rank in overall Chronic therapies with chronic mix of 62.3%. Key therapies like Respiratory, Anti-diabetes, Cardiac, Anti-infectives, and Urology outpace market growth. Trade Generics business has 2 brands with TTM revenue >INR 100 Cr and 5 brands with INR 50-100 Cr. Consumer Health anchor brands Nicotex, Omnigel and Cipladine ranked #1 in respective markets.
North America (differentiated assets, ANDA/NDA approvals) (21.0%)
Business obtained three significant drug approvals during the year: Lanreotide Injection (ANDA), Nilotinib Capsules (NDA) and Nano Paclitaxel (ANDA). China facility has commenced supply shipments, strengthening business operations. Delivered all-time high annual revenue of $934 Mn.
One Africa (South Africa, North Africa, Sub-Saharan Africa, Cipla Global Access) (14.0%)
South Africa prescription business maintains No.2 position in overall private market with secondary growth at 5.6% vs market growth of 3.8%. Growth propelled by uptick in key therapies, tender business and new launches. One Africa achieved robust quarterly growth of 15% YoY in USD terms and annual growth of 12% YoY in USD terms.
1 more statement
Emerging Markets & Europe
Deep market focus strategy has laid solid foundation with business delivering growth of 7-8% YoY in USD terms with uptick in both DTM (Direct to Market) and B2B categories, along with sustained overall margins.

Customers & channels

5 verified
Hospitals and institutional buyers
Cipla markets branded prescription drugs and acute care medications to institutional and hospital channels as part of India Rx business.
Retail pharmacies and trade generics channel
Trade Generics business supported by execution excellence in key therapies, new introductions and technological interventions.
Over-the-counter (OTC) consumers
Consumer Health anchor brands Nicotex, Omnigel and Cipladine in skin infection, pain relief, hydration, nicotine replacement and cold/cough categories.
2 more statements
North America: hospital systems, institutional buyers, specialty pharmacies
Cipla markets differentiated assets and generic drugs through specialty channels in North America with approvals for complex dosage forms.
Tender and public market buyers in Africa
One Africa private market growth propelled by uptick in key therapies, tender business as well as new launches.

Regulators

2 verified
USFDA and other regulatory bodies
Cipla depends on ability to obtain regulatory approvals for drugs and manufacturing facilities. North America business required ANDA (Abbreviated New Drug Application) and NDA (New Drug Application) approvals for Lanreotide Injection, Nilotinib Capsules and Nano Paclitaxel.
Drug regulatory authorities (India, Africa, Europe)
Cipla operates manufacturing sites across multiple countries and must comply with regulatory requirements for manufacturing, product approvals and market access in each jurisdiction.

Regulatory dependencies

3 verified
New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) approvals
Cipla's North America revenue depends on FDA approvals for new drugs and generic equivalents. Approval delays or rejections would reduce available products and revenue growth. Three significant approvals in FY26 strengthened the pipeline.
Antimicrobial Resistance (AMR) manufacturing standards
Cipla has committed to certifying one Antibiotic Product per India site as per AMR manufacturing standard by 2030. Regulatory tightening of AMR standards could increase manufacturing costs or limit product availability.
Environmental and ESG compliance for manufacturing
Cipla has committed to 80% renewable electricity share for India manufacturing, 30% absolute GHG reduction, water neutrality for India manufacturing, and zero waste to landfill. Regulatory tightening of environmental standards could increase manufacturing capital expenditure and operating costs.

Sensitivities

3 verified
Foreign exchange rates
Cipla earns 59% of revenue from North America (27%), One Africa (14%) and Emerging Markets & Europe (13%) as of Q3 FY26, and has significant international operations and exports. Appreciation of INR against USD and other foreign currencies would reduce rupee-converted foreign revenue and competitiveness.
Q3 EBITDA margin compression
EBITDA margin fell from 28.1% in Q3 FY25 to 17.7% in Q3 FY26 (-1,040 bps), indicating sensitivity to cost pressures, pricing pressures, or product/channel mix shifts.
North America pricing and reimbursement pressure
North America revenue declined 22% YoY in Q3 FY26 (INR 1,485 Cr vs INR 1,906 Cr Q3 FY25), indicating vulnerability to pricing erosion, increased generic competition, or reimbursement changes in that market.

Cost inputs

2 verified
Manufacturing labor and facility costs
Cipla operates global manufacturing operations across India, North America, Africa and China. Labor cost inflation and facility maintenance drive operating expenses. R&D represents 7.0-7.1% of revenue.
Energy and utility costs
Cipla has committed to 80% renewable electricity share for India manufacturing by 2030, indicating current reliance on grid electricity. Energy costs drive manufacturing expenses; transition to renewables has capital requirements but may reduce long-term operating costs.

Geographies

3 verified
North America (United States, Canada) (21.0%)
Cipla sells differentiated generic and specialty pharmaceutical assets. Obtained ANDA and NDA approvals for complex drugs. All-time high annual revenue of $934 Mn. Q3 FY26 revenue of INR 1,485 Cr (21% of total) declined 22% YoY.
Emerging Markets & Europe (13.0%)
Deep market focus strategy with business delivering growth of 7-8% YoY in USD terms with uptick in both DTM and B2B categories. Q3 FY26 revenue of INR 929 Cr represents 13% of total revenue.
China (manufacturing)
Cipla's China facility has commenced supply shipments for North America business, strengthening North America operations.
Each statement is checked word for word against the FY2026 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (23 Jul 2026).

Change log

8 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Corporate actionDividend - Rs 13 Per Share.
  3. Results filedQ4 FY2026 results filed.
  4. Results filedQ3 FY2026 results filed.
  5. Results filedQ2 FY2026 results filed.
  6. Results filedQ1 FY2026 results filed.
  7. Corporate actionDividend - Rs 13 Per Share/Special Dividend - Rs 3 Per Share.
  8. Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsWATCH on 30 of 30 flags judged; 1 red.
  • Data gapsDividend yield, PEG (vendor), Business quality: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓285 months of month-end prices, adjusted for bonuses and splits (1 corporate action)○no valuation of ours yet✓business-model card FY2026 · 43 verified

Questions people ask

What is Cipla's share price today?

Cipla last traded at ₹1,311.30 on the NSE, as of 12 Oct 2026, 11:00 pm IST, up 0.8% on the day, down 16.8% over a year. Its 52-week range is ₹1,166 to ₹1,673. The live price is in the app.

What is Cipla's market cap?

Cipla's market capitalisation is about ₹1.05 lakh crore: what it would cost to buy every share at today's price. That makes it the 92nd largest large cap company we cover.

Is Cipla Ltd a large cap, mid cap or small cap?

Cipla Ltd (CIPLA) is a large cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Cipla Ltd's P/E ratio?

31.17, vs peers 39.3 · 6th of 21. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Cipla Ltd overvalued?

Cheap, with low confidence: no valuation within 120 days; P/E 31.2 vs peers 39.3 (6th of 21); P/B 2.9 vs peers 6.2 (4th of 22). Cheap for a reason: A negative 5-year return.

How does Cipla Ltd make money?

Cipla Ltd is a pharmaceutical company that manufactures and sells branded prescription drugs, trade generics, consumer health products, and active pharmaceutical ingredients (APIs) across India, North America, Africa, and emerging markets. It earns revenue through sales of prescription medications, generic drugs, over-the-counter consumer wellness brands, and APIs to hospitals, pharmacies, distributors and consumers.

Who are Cipla Ltd's peers?

Compared with 21 Pharmaceuticals: Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Zydus Lifesciences Ltd, Laurus Labs Ltd, Dr Reddys Laboratories Ltd and 16 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Cipla do last quarter?

Cipla reported revenue of ₹7,077 Cr, up 5.3% on a year earlier and a net profit of ₹787 Cr, down 26.9% in the Jun 2026 quarter.

Who owns Cipla?

Cipla is held by promoters 29.1%, foreign institutions 20.1%, domestic institutions 34.5%.

Does Cipla pay a dividend?

Cipla last paid ₹13.00 a share, ex-dividend 5 Jun 2026; nothing in the past 12 months counts toward a yield.

What do analysts say about Cipla?

37 analysts cover Cipla, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Cipla, and 6,621 other companies, with 212 filters and the full peer tables

See Cipla in the app →See pricing